Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
Vale SA
VALE
KB Home
KBH
Apple
AAPL
US Stock MarketDetailed Quotes
ROIV Roivant Sciences
- 10.560
- +0.110+1.05%
Close Feb 14 16:00 ET
- 10.480
- -0.080-0.76%
Post 20:01 ET
7.54BMarket Cap-55.58P/E (TTM)
10.620High10.420Low3.22MVolume10.480Open10.450Pre Close33.88MTurnover0.89%Turnover Ratio2.02P/E (Static)713.55MShares13.05552wk High1.45P/B3.81BFloat Cap9.76052wk Low--Dividend TTM360.81MShs Float16.760Historical High--Div YieldTTM1.91%Amplitude2.520Historical Low10.527Avg Price1Lot Size
About Roivant Sciences Company
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Company Profile
SymbolROIV
Company NameRoivant Sciences
Listing DateDec 14, 2020
Founded2021
CEOMr. Matthew Gline
MarketNASDAQ
Employees908
Fiscal Year Ends03-31
Address50 Broadway,7th Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeSW1H 0BD
Phone44-207-400-3347
Websitehttp://www.roivant.com
Company Executives
- Name
- Position
- Salary
- Matthew Gline
- Chief Executive Officer and Director
- 738.19K
- Richard Pulik
- Chief Financial Officer
- 5.15M
- Dr. Mayukh Sukhatme
- President, Chief Investment Officer and Director
- 574.56K
- Dr. Eric Venker, M.D.,Pharm.D.
- President and Chief Operating Officer
- --
- Rakhi Kumar
- Chief Accounting Officer
- 4.33M
- Ilan Oren
- Chairman of the Board
- 488.49K
- Melissa B. Epperly
- Independent Director
- 444.24K
- Keith Manchester, M.D.
- Independent Director
- 442.59K
- Daniel Gold
- Independent Director
- 449.24K
- James C. Momtazee
- Independent Director
- 459.24K
- Meghan M. Fitzgerald, Ph.
- Independent Director
- 941.68K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.